Trifluoroacetylation potentiates the humoral immune response to halothane in the Guinea PIG

Kenneth L. Hastings, Cynthia Thomas, Alan P. Brown, A Jay Gandolfi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Halothane hepatitis appears to result from an inappropriate immune response to the products of halothane metabolism. Attempts to produce an animal model for halothane hepatitis have been largely unsuccessful. Although guinea pigs produce neoantigens following treatment with halothane, the subsequent antibody response is weak, possibly accounting for the failure to produce halothane hepatitis in these animals. In order to increase the antibody response to halothane neoantigens, three methods for trifluoroacetylating proteins were used. Guinea pigs were either treated with S-ethylthiotrifluoroacetate, autologous lymphocytes trifluoroacetylated ex vivo, or immunized with trifluoroacetylated mycobacterial protein, followed by exposure to halothane, and examined for anti-halothane metabolite antibodies (anti-TFA antibodies). Animals treated with S-ethylthiotrifluoroacetate developed anti-TFA antibodies, and following exposure to halothane exhibited an enhanced antibody response. Treatment with trifluoroacetylated lymphocytes also resulted in an enhanced anti-TFA antibody response following halothane exposure. Immunization with trifluoroacetylated mycobacterial proteins resulted in very high anti-TFA antibody titers. However, subsequent exposure to halothane had no observable effect on specific antibody titers. Exposure to halothane, regardless of treatment, resulted in the production of anti-microsomal protein antibodies. Signs of halothane hepatitis were not observed, indicating that enhancement of the humoral immune response does not appear to be sufficient for production of halothane hepatitis.

Original languageEnglish (US)
Pages (from-to)201-213
Number of pages13
JournalImmunopharmacology and Immunotoxicology
Volume17
Issue number1
DOIs
StatePublished - 1995

Fingerprint

Guinea
Halothane
Humoral Immunity
Antibody Formation
Anti-Idiotypic Antibodies
Antibodies
Guinea Pigs
Proteins
Animals
Lymphocytes
Immunization
Therapeutics
Animal Models
Halothane Hepatitis
Metabolites
Metabolism

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Trifluoroacetylation potentiates the humoral immune response to halothane in the Guinea PIG. / Hastings, Kenneth L.; Thomas, Cynthia; Brown, Alan P.; Gandolfi, A Jay.

In: Immunopharmacology and Immunotoxicology, Vol. 17, No. 1, 1995, p. 201-213.

Research output: Contribution to journalArticle

Hastings, Kenneth L. ; Thomas, Cynthia ; Brown, Alan P. ; Gandolfi, A Jay. / Trifluoroacetylation potentiates the humoral immune response to halothane in the Guinea PIG. In: Immunopharmacology and Immunotoxicology. 1995 ; Vol. 17, No. 1. pp. 201-213.
@article{580711dd376948698c788af1b5522283,
title = "Trifluoroacetylation potentiates the humoral immune response to halothane in the Guinea PIG",
abstract = "Halothane hepatitis appears to result from an inappropriate immune response to the products of halothane metabolism. Attempts to produce an animal model for halothane hepatitis have been largely unsuccessful. Although guinea pigs produce neoantigens following treatment with halothane, the subsequent antibody response is weak, possibly accounting for the failure to produce halothane hepatitis in these animals. In order to increase the antibody response to halothane neoantigens, three methods for trifluoroacetylating proteins were used. Guinea pigs were either treated with S-ethylthiotrifluoroacetate, autologous lymphocytes trifluoroacetylated ex vivo, or immunized with trifluoroacetylated mycobacterial protein, followed by exposure to halothane, and examined for anti-halothane metabolite antibodies (anti-TFA antibodies). Animals treated with S-ethylthiotrifluoroacetate developed anti-TFA antibodies, and following exposure to halothane exhibited an enhanced antibody response. Treatment with trifluoroacetylated lymphocytes also resulted in an enhanced anti-TFA antibody response following halothane exposure. Immunization with trifluoroacetylated mycobacterial proteins resulted in very high anti-TFA antibody titers. However, subsequent exposure to halothane had no observable effect on specific antibody titers. Exposure to halothane, regardless of treatment, resulted in the production of anti-microsomal protein antibodies. Signs of halothane hepatitis were not observed, indicating that enhancement of the humoral immune response does not appear to be sufficient for production of halothane hepatitis.",
author = "Hastings, {Kenneth L.} and Cynthia Thomas and Brown, {Alan P.} and Gandolfi, {A Jay}",
year = "1995",
doi = "10.3109/08923979509052729",
language = "English (US)",
volume = "17",
pages = "201--213",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Trifluoroacetylation potentiates the humoral immune response to halothane in the Guinea PIG

AU - Hastings, Kenneth L.

AU - Thomas, Cynthia

AU - Brown, Alan P.

AU - Gandolfi, A Jay

PY - 1995

Y1 - 1995

N2 - Halothane hepatitis appears to result from an inappropriate immune response to the products of halothane metabolism. Attempts to produce an animal model for halothane hepatitis have been largely unsuccessful. Although guinea pigs produce neoantigens following treatment with halothane, the subsequent antibody response is weak, possibly accounting for the failure to produce halothane hepatitis in these animals. In order to increase the antibody response to halothane neoantigens, three methods for trifluoroacetylating proteins were used. Guinea pigs were either treated with S-ethylthiotrifluoroacetate, autologous lymphocytes trifluoroacetylated ex vivo, or immunized with trifluoroacetylated mycobacterial protein, followed by exposure to halothane, and examined for anti-halothane metabolite antibodies (anti-TFA antibodies). Animals treated with S-ethylthiotrifluoroacetate developed anti-TFA antibodies, and following exposure to halothane exhibited an enhanced antibody response. Treatment with trifluoroacetylated lymphocytes also resulted in an enhanced anti-TFA antibody response following halothane exposure. Immunization with trifluoroacetylated mycobacterial proteins resulted in very high anti-TFA antibody titers. However, subsequent exposure to halothane had no observable effect on specific antibody titers. Exposure to halothane, regardless of treatment, resulted in the production of anti-microsomal protein antibodies. Signs of halothane hepatitis were not observed, indicating that enhancement of the humoral immune response does not appear to be sufficient for production of halothane hepatitis.

AB - Halothane hepatitis appears to result from an inappropriate immune response to the products of halothane metabolism. Attempts to produce an animal model for halothane hepatitis have been largely unsuccessful. Although guinea pigs produce neoantigens following treatment with halothane, the subsequent antibody response is weak, possibly accounting for the failure to produce halothane hepatitis in these animals. In order to increase the antibody response to halothane neoantigens, three methods for trifluoroacetylating proteins were used. Guinea pigs were either treated with S-ethylthiotrifluoroacetate, autologous lymphocytes trifluoroacetylated ex vivo, or immunized with trifluoroacetylated mycobacterial protein, followed by exposure to halothane, and examined for anti-halothane metabolite antibodies (anti-TFA antibodies). Animals treated with S-ethylthiotrifluoroacetate developed anti-TFA antibodies, and following exposure to halothane exhibited an enhanced antibody response. Treatment with trifluoroacetylated lymphocytes also resulted in an enhanced anti-TFA antibody response following halothane exposure. Immunization with trifluoroacetylated mycobacterial proteins resulted in very high anti-TFA antibody titers. However, subsequent exposure to halothane had no observable effect on specific antibody titers. Exposure to halothane, regardless of treatment, resulted in the production of anti-microsomal protein antibodies. Signs of halothane hepatitis were not observed, indicating that enhancement of the humoral immune response does not appear to be sufficient for production of halothane hepatitis.

UR - http://www.scopus.com/inward/record.url?scp=0028922204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028922204&partnerID=8YFLogxK

U2 - 10.3109/08923979509052729

DO - 10.3109/08923979509052729

M3 - Article

C2 - 7759772

AN - SCOPUS:0028922204

VL - 17

SP - 201

EP - 213

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 1

ER -